How SGLT2-inhibitors exert such striking clinical benefits in HF is not completely known, and their beneficial effects cannot be simply explained by their actions on glycemic control, or as osmotic diuretics [5]. The gene discussed is SLC5A2; the disease is hydrops fetalis.